4.1 Article

Impulsivity in Adolescents with Bipolar Disorder and/or Attention-Deficit/Hyperactivity Disorder and Healthy Controls as Measured by the Barratt Impulsiveness Scale

期刊

出版社

MARY ANN LIEBERT, INC
DOI: 10.1089/cap.2010.0096

关键词

-

资金

  1. NIMH [K23MH063373]
  2. AstraZeneca
  3. BMS/Otsuka
  4. Lilly
  5. GSK
  6. Pfizer
  7. J J
  8. Shire
  9. Abbott
  10. Janssen
  11. Martek
  12. Somerset
  13. Repligen
  14. Sumitomo
  15. NIDA
  16. NIAAA
  17. NARSAD
  18. Otsuka
  19. Eli Lilly
  20. Abbott Laboratories
  21. Janssen (Johnson Johnson)
  22. Bristol Myers Squibb
  23. AstraZenecha
  24. Martek Biosciences
  25. Nutrition 21

向作者/读者索取更多资源

Objective: To compare the type and degree of impulsivity among adolescents with bipolar disorder (BD), adolescents with attention-deficit/hyperactivity disorder (ADHD), and healthy comparison subjects using the Barratt Impulsiveness Scale, Version 11 (BIS-11). Methods: Manic adolescents with BD (n = 31), adolescents with ADHD (n = 30), and healthy subjects (n = 25) completed the BIS-11, a 30-item, self-report scale with three subscales (cognitive, motor, and nonplanning). The BIS-11 total and subscale scores were compared among groups. We also examined associations among the BIS-11, Young Mania Rating Scale and co-occurring disruptive behavioral disorders (DBDs) within the BD group. Results: Total and each subscale scores were significantly higher for the BD group than for the healthy controls (p < 0.05). The total scores and the cognitive and motor subscale scores were significantly higher for the ADHD group than for the healthy control group (p < 0.05). However, there was no statistically significant difference between the nonplanning subscale scores of the ADHD group and the healthy control group (p > 0.05). There were no significant differences between the BD and ADHD groups or between the BD groups with and without ADHD. The BD patients with DBDs (i.e., oppositional defiant disorder or conduct disorder) scored significantly higher on the motor subscale than did BD patients without DBDs. There were no statistically significant associations between the Young Mania Rating Scale and BIS-11 scores within the BD group. Conclusion: Our findings suggest that impulsivity is elevated in adolescents with BD as well as adolescents with ADHD, except for nonplanning impulsivity, which was not significantly different between adolescents with ADHD and the healthy comparison group. This may suggest that nonplanning impulsivity is relatively specific to adolescents with BD. Additionally, our data indicate that elevations in impulsivity, as measured by the BIS-11, may be independent of symptoms severity and, therefore, may be a stable, trait-related component of BD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据